Document is current
Any future updates will be listed below
-
Authors
van der Kleij, Maud B. A. https://orcid.org/0009-0008-8492-8039
Guchelaar, Niels A. D. https://orcid.org/0000-0001-8080-9093
Meertens, Marinda
Westerdijk, Kim
Giraud, Eline L.
Bleckman, Roos F.
Groenland, Stefanie L. https://orcid.org/0000-0002-5085-3787
van Eerden, Ruben A. G. https://orcid.org/0000-0001-8937-3425
Imholz, Alex L. T.
Vulink, Annelie J. E.
Otten, Hans-Martin
Fiebrich-Westra, Helle-Brit
Lubberman, Floor J. E.
Desar, Ingrid M. E.
Moes, Dirk-Jan A. R. https://orcid.org/0000-0003-3219-253X
Touw, Daan J.
Koolen, Stijn L. W.
Gelderblom, Hans
Reyners, An K. L. https://orcid.org/0000-0003-1678-7816
van Erp, Nielka P.
Mathijssen, Ron H. J. https://orcid.org/0000-0001-5667-5697
Huitema, Alwin D. R.
,
Steeghs, Neeltje https://orcid.org/0000-0003-2989-2279
-
Funding
Funding for this research was provided by:
Ipsen Fund (Unrestricted grant, no grant number)
GlaxoSmithKline (Unrestricted grant, no grant number)
Novartis (Unrestricted grant, no grant number)
Pfizer (Unrestricted grant, no grant number)
Roche (Unrestricted grant, no grant number)
- License Information
-
More Information
Article History
Received: 15 April 2024
Revised: 25 June 2024
Accepted: 1 July 2024
First Online: 6 July 2024
Competing interests
: MBAvdK, NADG, MM, KW, ELG, RFB, SLG, RAGvE, ALTI, AJEV, HMO, H-BFW, FJEL, IMED, DJARM, DJT, SLWK and ADRH declare that they do not have any financial or personal conflicting interests. HG reports institutional research funding from Daiichi Sankyo, Deciphera Pharmaceuticals, Novartis, Boehringer Ingelheim, AmMax Bio, Debiopharm, Cytovation; all outside the submitted work. AKLR reports institutional research funding from Merck and Tesaro; all outside the submitted work. NPvE reports research funding paid to the institute from Astellas, Ipsen; all outside the submitted work. RHJM reports research funding paid to the institute from Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Deuter Oncology, Nordic Pharma, Novartis, Pamgene, Pfizer, Roche, Sanofi, and Servier; all outside the submitted work. NS reports research grants paid to the institute from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Cresecendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda; all outside the submitted work. NS provided consultation or attended advisory boards for Boehringer Ingelheim, Cogent Biosciences, Ellipses Pharma, Incyte, Luszana.
: The DPOG-TDM study was approved by the Institiutional Review Board of the Netherlands Cancer Institute (Amsterdam, the Netherlands) and by each individual participating hospital. All patients provided written informed consent. The study was performed in accordance with the Declaration of Helsinki.
